Gene Therapy for Sickle Cell Could Be Cost-Effective in Uganda - Summary - MDSpire
Feature

Gene Therapy for Sickle Cell Could Be Cost-Effective in Uganda

New modeling study shows curative treatments may be viable in low-income settings if costs are scaled and societal benefits included

  • April 9, 2026

  • 2 min

Share

A recent modeling study indicates that gene therapy for sickle cell disease (SCD) could be cost-effective in Uganda if treatment prices are significantly reduced and broader societal benefits are considered. Researchers adapted U.S. economic models to local contexts, analyzing two therapies—Casgevy and Lyfgenia. The study found Uganda's lifetime standard-of-care cost for SCD to be just $21,877, highlighting the need for major price adjustments. Casgevy was identified as the more viable option due to its favorable cost-effectiveness ratio, particularly when societal gains are included.

Original Source(s)

Gene Therapy for Sickle Cell Could Be Cost-Effective in Uganda

  • April 9, 2026

Related Content

Rare COVID Vaccine Clotting Linked to Adenoviral Protein 

Antibody proteomics and immunogenetics identify adenoviral protein VII as the trigger of PF4-targeting antibodies 

  • April 21, 2026

  • 2 min
Dynamic, Accessible Risk Stratification Tool Created for Smoldering Multiple Myeloma

Researchers have developed a dynamic risk stratification tool for patients with smoldering multiple myeloma to predict their chance of progression to active multiple myeloma. The tool, called Precurso...

ASH 2025: Myelofibrosis Roundup

For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being pa...